Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
about
Vaccinology in the third millennium: scientific and social challengesQuantifying the Epidemiological Impact of Vector Control on DengueCircumsporozoite protein as a potential target for antimalarialsPlasmodium malaria and antimalarial antibodies in the first year of lifeProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemTafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to dateHow Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?Determinants of early life immune responses to RSV infectionTools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria?Self-assembling protein nanoparticles in the design of vaccinesExpanding the antimalarial toolkit: Targeting host-parasite interactionsMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaMalaria vaccines: identifying Plasmodium falciparum liver-stage targetsOpen Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos ArylpyrrolesThe time-course of protection of the RTS,S vaccine against malaria infections and clinical diseaseZikaVR: An Integrated Zika Virus Resource for Genomics, Proteomics, Phylogenetic and Therapeutic AnalysisFebrile illness diagnostics and the malaria-industrial complex: a socio-environmental perspective.Identification of Plasmodium falciparum Translation Initiation eIF2β Subunit: Direct Interaction with Protein Phosphatase Type 1Protective immunity to liver-stage malariaTransmission-blocking strategies: the roadmap from laboratory bench to the communityThe March Toward Malaria VaccinesDomestic trends in malaria research and development in China and its global influenceNew developments in anti-malarial target candidate and product profilesIn-silico screening, identification and validation of a novel vaccine candidate in the fight against Plasmodium falciparumSeasonal vaccination against malaria: a potential use for an imperfect malaria vaccine.The Immunologic Complexity of Growing Up with Malaria--Is Scientific Understanding Coming of Age?In vivo curative and protective potential of orally administered 5-aminolevulinic acid plus ferrous ion against malaria.Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialCosting RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data.Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screeningEnhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand.Host-Parasite Interactions in Human Malaria: Clinical Implications of Basic ResearchParasite Carbohydrate Vaccines.Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities.Blood Stage Malaria Disrupts Humoral Immunity to the Pre-erythrocytic Stage Circumsporozoite Protein.Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.
P2860
Q24261399-3FDC482D-D58C-4FB2-B7C3-CF44F07F359AQ24278786-826D8F12-A6CE-4969-A63C-6BB34E89F9CAQ26314437-522C59B4-5624-4820-A2B4-423138F470ADQ26315542-995B5802-EE29-4141-9A4C-DC3DD30AEA29Q26700012-ABA383F0-0C54-49F2-AD33-0702D0340356Q26741307-0E316CE3-DA66-4EE6-99E9-E699028B440DQ26748155-16D66774-9E3E-4EEE-B048-7681F84A2C9DQ26764790-22EA0972-2E96-431B-BB1D-8DA65D323F89Q26765029-9B77C8DF-47DE-4058-B315-4093449B5EEBQ26767097-CB907E43-7810-4535-BD8A-13B78C01025FQ26772866-6E6DD712-02AE-4F33-A4E1-37A9FC154BE7Q26772878-0DB285E2-8EDE-47EB-9C60-DB83A452F4DAQ26781372-AF620B1E-C3D0-430C-8B6A-18BC8CDAC745Q26883657-AEAC23B9-6320-41A6-BC2B-49AFC716F01DQ27304630-DAED07C7-2225-44E5-BE08-035C8E3B3907Q27468686-C65822FF-3099-4103-B9A9-77862B524BD6Q27928033-DC4429D4-497C-4B17-B449-48D6771FF389Q27973366-72C4F740-D52B-4D0F-81B7-90124DD4F905Q28068626-EEA1B450-8C05-4662-BB4C-9C2449031439Q28078982-E3836744-130B-4B31-B5EA-2A19BE413084Q28084325-7F9C0D28-4D88-4ADA-9CB8-86A3475667ECQ28365208-2A7A2812-520E-4991-AA37-F233CEC0F8A1Q28468598-A1AF5F29-F239-4CC7-926F-1E84CB446BCCQ30041123-25B5E133-BD20-4DB5-887C-0F8A5BD3CE45Q30234589-FDC91013-6630-43F6-8C63-F5021C650E80Q30382403-4EB3128E-D1E8-4347-9899-80302574D21FQ30386961-09F1D68F-01F0-492D-94F1-AEE4EB5AD17AQ30390705-E5E8A12F-F154-499C-B287-2FE26F280496Q30400132-79268AFF-5B06-4942-9F9B-8257B7577DF1Q30991737-B43E5AAC-B734-43BB-B631-72BBEF3C79E4Q31013590-2096794C-1B36-4608-84B2-388AA1DEFDA1Q33560788-08643B49-A3FA-44E1-8F45-87F00E014711Q33577093-6FC46FCC-BAD9-4A44-8592-2487A7238EA4Q33617694-11FA9254-7D61-4932-93D6-A340B33FD689Q33701044-82E4A6D7-2823-4B57-9267-96465EFB980BQ33785863-CFC6874E-6F75-4DA3-A41A-9FCB8502C5E7Q33808603-92389573-E22F-47FA-9DDC-31A13C82D3ABQ33811954-3C947F44-FD18-4C87-A20F-7C9924407E63Q34509612-E45459E7-526B-43AA-8370-47E717E5AA1EQ34530710-A1B58A8F-828C-4274-9B83-6116E7008472
P2860
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@ast
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@en
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@nl
type
label
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@ast
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@en
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@nl
prefLabel
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@ast
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@en
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@nl
P2860
P1433
P1476
Efficacy and safety of RTS,S/A ...... randomised, controlled trial.
@en
P2093
RTS,S Clinical Trials Partnership
P2860
P356
10.1016/S0140-6736(15)60721-8
P407
P577
2015-04-23T00:00:00Z